Skip to content

Preview build — content shown is placeholder, pending ESPD review.

ESPD European Society for Photodermatology
Heliora Laboratories Cutisol Pharma Actinova Dermocosmetics Solenta Skin Science Luviderm Labs Photalia Pharma
Supporters
← Journal
Clinical study March 2026 · Volume —, Sample issue

Narrow-Band UVB Phototherapy in Moderate Plaque Psoriasis: An Illustrative Treatment-Response Profile

Sample contribution — author list to be confirmed

Sample article — illustrative content for this prototype, not a peer-reviewed publication. Figures present representative rather than empirical data.

Abstract

Narrow-band UVB phototherapy remains a first-line treatment for moderate plaque psoriasis. This illustrative summary presents a representative treatment-response profile across twelve weeks of standardised NB-UVB delivery and discusses implications for clinical scheduling and patient selection. Sample article and figure — provided for this prototype.

Narrow-band ultraviolet B (NB-UVB, ~311 nm) phototherapy is well established in the management of moderate-to-severe plaque psoriasis, balancing therapeutic efficacy against a favourable acute and chronic safety profile.

Clinical response is conventionally tracked using the Psoriasis Area and Severity Index (PASI), with meaningful improvement typically expressed as a percentage reduction from baseline.

Background

NB-UVB exerts its therapeutic effect principally through induction of T-cell apoptosis and modulation of keratinocyte proliferation, restoring a more orderly pattern of epidermal turnover.

Standard regimens involve thrice-weekly sessions, with dose increments guided by minimal erythema dose testing or skin phototype-based protocols.

Representative results

A representative twelve-week treatment course produces a roughly monotonic reduction in mean PASI, with the greatest absolute change typically observed in the first six weeks of therapy.

Most patients reach a clinically meaningful endpoint (PASI 75) by the end of a standard course, with a smaller proportion progressing to PASI 90.

25 20 15 10 5 0 0 2 4 6 8 10 12 Treatment week Mean PASI
Figure. Mean PASI score across twelve weeks of NB-UVB therapy. Illustrative — sample data for this prototype.

Discussion

The response profile supports a structured initial course of approximately twelve weeks before reassessment, with later maintenance strategies tailored to individual relapse patterns.

Patient selection remains central: skin phototype, comorbidity, prior phototherapy exposure and adherence to scheduled sessions all materially influence the clinical trajectory.

Conclusion

NB-UVB remains a valuable, well-tolerated option in moderate plaque psoriasis. Realistic expectations about response timing — informed by representative trajectories such as the one shown here — help align patient and clinician on treatment goals.